Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines

Q-Vant Biosciences

Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune response to vaccine antigens and is a vital component in more than 17 human vaccine candidates, including the FDA-approved GSK Shingrix® shingles vaccine and the WHO-authorized, GSK Mosquirix® malaria vaccine. In addition, saponin-based adjuvants are a key component in the Novavax COVID-19 vaccine, which has been shown to be highly effective in clinical trials and has recently been authorized for emergency use by the European Union (EU) and the World Health Organization (WHO). Q-VANT is led by a team with world-class knowledge of vaccine and adjuvant development, Quillaja extract supply, processing, formulation, purification quantification R&D and application, and decades of experience in pharmaceutical R&D, supply chain, manufacturing, commercialization, and regulatory approvals. Chief Executive Officer, Doug Klaiber, is joined by Chief Commercial Officer, Juan Jose Albarran, and Chief Operating Officer, Hans Konsens. The team was recently rounded out by three robust additions including Chief Scientific Officer Bruce Forrest, MD, MBA; Vice President of Regulatory Affairs Jack Love, PhD; and Vice President of Business Development, Stein Lokstad. “Bruce, Jack and Stein bring unparalleled leadership expertise, insights and connections gleaned from their decades working at the likes of companies such as Pfizer and Brenntag Biosector,” said Doug Klaiber, Chief Executive Officer, Q-VANT Biosciences. “Their experience in successfully bringing some of the world’s leading vaccines and adjuvants to market will be invaluable as we scale our efforts to produce as much of this highly valuable adjuvant as is needed.” QS-21 is traditionally extracted from the bark of mature trees native to Chile known as the Quillaja saponaria -- a harvesting process that negatively impacts the forest and the sustainability of the resource. Today, with regulatory restrictions on deforestation of this tree, and projected demand for QS-21 in the billions of doses annually, shortages of QS-21 are affecting the pharmaceutical market’s ability to meet the surging need for vaccine dosages globally. Q-VANT’s Q-SAP™ (Quillaja Sustainable Adjuvant Platform) is a technology platform combining computational learning techniques and a proprietary multi-step purification process to systematically enhance Quillaja sourcing options and to drive extremely effective outputs. The first of its kind, Q-SAP enables Q-VANT to obtain adjuvant products from a wide range of Quillaja-based plant materials, which can increase production volumes by as much as 1,000, leading to billions of doses in a 100% sustainable way. “The market opportunity has expanded rapidly for QS-21 as an adjuvant, especially with the race to research, develop and produce vaccines to combat COVID-19,” said Juan Jose Albarran, Chief Commercial Officer, Q-VANT Biosciences. “Our technology is not only able to fulfill the growing demand for QS-21, but also do it in a fully sustainable way which protects the forest and long-term stability of the supply for the adjuvant.” The company is ramping up its pharma cGMP production and in the process of submitting a Drug Master File (DMF) with FDA in 2022. About Q-VANT Biosciences Q-VANT is a privately held company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company's next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000% enabling the production of billions of doses annually to meet today's increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Hillary Lima +1 401-490-9700 hillary.lima@svmpr.com Company Website https://q-vant.com/

January 06, 2022 08:00 AM Eastern Standard Time

Michael Edwards CEO MedMinder Announcement

MedMinder

MedMinder Systems Inc. (“MedMinder”), the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution, today announced that Michael F. Edwards has been appointed as Chief Executive Officer. “I am delighted to welcome Mike as our new Chief Executive Officer,” said David Shulkin M.D., Chairman of the Board of Directors of MedMinder. “The COVID-19 Pandemic has highlighted the critical importance of access to medications and remote care. MedMinder is purpose built to assist polychronic patients improve medication adherence and simplify digital care solutions. Mike brings the right set of skills and experience to build upon MedMinder’s platform and take the organization to the next level. Finally, I would like to thank Eran Shavelsky, the founder of MedMinder who led the company from inception into becoming a leading provider of online pharmacy and connected care solutions. Eran’s vision and persistence made MedMinder what it is today.” “I am so proud of the MedMinder team for building such a valuable digital health solution which helps so many people,” said Eran Shavelsky, MedMinder Founder. “I am confident that under Mike’s leadership the company will further grow and expand.” Mike has a passion for helping solve some of the biggest problems in healthcare. As a veteran healthcare executive Mike has built and led high performing organizations within pharmacy, technology and consumer engagement. Prior to joining MedMinder, Mike was Chief Commercial Officer at Truveris. Mike held various executive roles at Optum, a subsidiary of United Health Group (NYSE:UNH). Most recently Mike was President, Commercial Markets at OptumRx. Prior to that role, Mike was part of the executive team at Catamaran where he was instrumental in executing the integration with Optum. Mike held leadership positions at Vitals, Express Scripts and Medco, where he began his healthcare career. Mike holds a bachelor’s degree from Rutgers University and a Masters degree from NJIT in International Business Finance as well as an MBA in the Management of Technology. Mr. Edwards commented: “I’m impressed by MedMinder’s unique ability to engage customers, deliver measurable health outcomes, and simplify the inherent complexity associated with pharmacy care. I look forward to being part of a team with a restless ambition to improve patient experiences and unlock the potential of combining pharmaceutical and digital care.” ABOUT MEDMINDER MedMinder is the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients. Founded in 2007 by Eran Shavlelsky, MedMinder currently employs over 150 team members between its Massachusetts and New York locations and is recognized as an ultra-high-growth digital healthcare company. MedMinder’s touch screen-enabled, automatic pill dispenser is the first device on the market capable of delivering medications from its pharmacy directly to patients’ doors in pre-organized daily trays for the entire month. With a customer-first approach, MedMinder is continually innovating to improve and meet the evolving needs of patients, caregivers, practitioners and payors. More information can be found at https://www.medminder.pharmacy. Contact Details MedMinder Systems Inc. Ethan Davis +1 339-777-4662 ethan.davis@medminder.com Company Website https://www.medminder.pharmacy

January 05, 2022 12:00 PM Eastern Standard Time

Cortland Biomedical Announces New Product Development Team Appointments to Support Continued Growth

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, today announced the appointment of three new hires to its New Project Development team. Robert Demaree has been appointed as a Senior Process Engineer. He brings 25 years of experience in various technical roles throughout his career with experience in development of fiber optic cable processes, printed circuit board materials, and electrical generators. He also served as a subject matter expert in composite materials and management of the chemistry group at IMR Test Labs. Rob holds a bachelor’s degree in Mechanical Engineering and a master’s degree in Materials Science and Engineering from Virginia Polytechnic Institute. Tony Maslowski joins the team as a Senior Project Manager to oversee new product development programs and drive projects toward timely completion. He brings more than 30 years of experience in various technical and project management roles throughout his career. He has worked in the chemical and medical device industries, notably with companies such as DePuy and Aesculap. Tony holds a bachelor’s degree in Ceramic Science and Engineering from Penn State and an MBA from Temple University. Additionally, Tony is co-owner of two US patents and holds several certifications in project management. Zach Robbins has been hired as a Textile Process Engineer to help develop processes related to knit and woven fabric product development projects. Zach comes to Cortland with four years of experience in the textile industry, most recently working with finishing and dyeing of knitted products at Gehring Tricot. He holds a bachelor’s degree in Materials Science Engineering – Polymers, Textiles and Fibers from Georgia Tech. Cortland Biomedical’s team nearly doubled in size during the 2021 calendar year, with a particular focus on engineering hires to support its robust new product pipeline. The company is looking to fill additional positions across engineering, manufacturing and administrative support. “We’re proud to be growing in the Cortland Community and continuing to add topnotch talent to further our mission of adding maximum value and innovation to meet our customers’ needs for custom biomedical textile solutions fabricated for their specific medical device applications,” said Eric Brown, Director of Operations, Cortland Biomedical. “We welcome Robert, Tony and Zach to the team and look forward to seeing their contributions to new product development in the year ahead.” In 2021, Cortland completed the transition to its state-of-the-art facility, which construction began on in 2018. Cortland’s ISO 13485:2016 -certified facility on Lime Hollow Rd. has 20,000 sq.ft. of cleanroom manufacturing space, with Class 7 and Class 8 cleanrooms third party-certified to ISO14644. It also features a qualified ASTM Type 1-B water system with sustained monitoring. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 05, 2022 10:05 AM Eastern Standard Time

The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation

Quidel Corporation

An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories. Borrelia burgdorferi, the bacterium that causes Lyme disease, is also discussed as a coinfection on this PACE-accredited webinar, the third in a series hosted by Quidel Corporation (Nasdaq: QDEL) in collaboration with Global Lyme Alliance. Titled “The Diversity of Bartonellosis Manifestations and Challenges to Treatment,” the webinar is conducted by Monica E. Embers, Ph.D.,* associate professor of microbiology and immunology and director of vector-borne disease research at Tulane National Primate Research Center in Covington, Louisiana. Her research at Tulane focuses on the effectiveness of antibiotics and other therapeutics to eradicate Borrelia burgdorferi from the body while also exploring the many avenues related to persistent Lyme disease. Dr. Embers currently serves on the 2021 Tick-Borne Disease Working Group, which was established by Congress as part of the 21st Century Cures Act. Appointed to this position by the U.S. Department of Health and Human Services, the Working Group serves as a federal advisory committee to provide expertise and recommendations regarding all tick-borne diseases, evaluate tick-borne disease research priorities and help ensure coordination between federal agencies. The primary function of the Working Group is the development of a report of findings and recommendations regarding the federal response to tick-borne disease prevention, treatment and research, which it submits to Congress and the Secretary of Health and Human Services. On the webinar, Dr. Embers describes the possible clinical presentations (signs and symptoms) of Bartonellosis; compares Bartonellosis to Lyme borreliosis in terms of detection, persistence and treatment; and identifies research efforts needed to better diagnose and cure Bartonellosis. The timing and relevance for the webinar is particularly important as Lyme disease is on the rise to record numbers throughout the country and potentially affected as many as 476,000 citizens in 2021. Among those invited to view the webinar are physicians; allied health professionals; health researchers; and representatives of physician offices, laboratories, urgent care centers, patient advocacy associations and others interested in the subject. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. *Dr. Embers receives an honorarium for conducting the webinar sponsored by Quidel. Contact Details breakwhitelight JAMES YEAGER +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

January 05, 2022 06:00 AM Pacific Standard Time

AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022

Appyea

AppYea (OTC: APYP), a medical device technology company, announced today the deemed completion of its previously announced acquisiiton of SleepX, an innovative medical device company focused on the development of SleepX’s flagship product DreamIT – an uncompetitively accurate wearable monitoring solution to treat sleep apnea and snoring and fundamentally improve quality of life. After the acquisiiton, SleepX will continue operating under its own brand name as a fully owned AppYea subsidiary. The merged company will focus on further development and commercialization of SleepX’s solution, including continued R&D investments and new initiatives in sales and marketing. Also, SleepX intends to begin a calibration trial with DreamIT. “I am delighted that we have completed the acquisition of SleepX. The company develops a wearble technology solution to treat snoring and sleep apnea, which is patent protected in the US, EU and Israel, and caters to two growing markets in high demand", said Boris (Bary) Molchadsky, AppYea’s Chairman. “This aqisition allows us to execute our growth strategy towards the beginning of DreamIT’s marketing during the second half of 2022, while continuing its development with the Biomedical Department at Ben Gurion University in Israel, and launching our first calibaration trial. Meanwhile, we are examining the acquisition of other synergetic activities that will complement the SleepX vision to improve sleep quality and quality of life globally.” According to the market intelligence company Fior Markets, the global anti-snoring treatment market is expected to grow at a 9.07% CAGR to USD 8.6 billion by 2028. The global sleep apnea devices market is expected to grow at a 6.2% CAGR to USD 6.1 billion by 2028, according to Grand View Research’s report. About SleepX SleepX, an AppYea (OTC: APYP) subsidiary, is a medical device company, focused on the development of uncompetitively accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life. The company’s solutions are based on its proprietary IP portfolio of AI and sensing technologies for the tracking, analysis, and diagnosis of vital signs and other physical parameters during sleep time, offering extreme accuracy and resistance at affordable cost. SleepX’s flagship solution is DreamIT – a patented wristband communicating with its smartphone app to gently vibrate with every breathing interruption, and cause a shift from deep to lighter sleep, training the brain to breath properly. The app tracks sleep patterns and using the company’s machine learning technology to adapt the treatment and recommend improvements according to the user’s sleep and breathing patterns. In addition to reducing snoring and improving sleep quality, users will be able to access important statistics relating to their sleep patterns via the app to track and detect anomalies over time. DreamIT is being developed in collaboration with the Biomedical department of the Ben Gurion University of the Negev and is patent protected in the US, EU and Israel. According to the market intelligence company Fior Markets, the Global Anti-Snoring Treatment Market is expected to grow to USD 8.6 billion by 2028, at a 9.07% CAGR during 2021-2028. The global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a 6.2% CAGR from 2021 to 2028, reaching USD 6.1 billion by 2028, according to a new report by Grand View Research, Inc SleepX was founded in 2019, and following the acquisition, its headquarters are in Boca Raton, Florida. Safe Harbor and Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to our ability to raise capital needed to develop amd market our products, our ability to maange the business post acquisition, economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

December 31, 2021 08:45 AM Eastern Standard Time

Video Image

METER Group Unveils Major Update to AQUALAB Vapor Sorption Analyzer Software

METER Group, Inc.

Moisture Analysis Toolkit enables food and pharma manufacturers to address ingredient source changes, accelerate product formulation, extend shelf life, and employ the most cost-effective packaging using research-tested predictive models that present complex isotherm and water activity data as clear, actionable insights METER Group, Inc. USA (METER) today unveiled a major update to the AQUALAB Vapor Sorption Analyzer (VSA) Moisture Analysis Toolkit, enabling food and pharma companies to harness analytics and predictive modeling that accelerates product formulation, maximizes cost-efficiency of packaging, and extends shelf life. The AQUALAB VSA Moisture Analysis Toolkit (MAT) is a first-of-its-kind, intuitive, full-featured modeling solution that transforms moisture data into solutions using research-tested predictive models. This software helps overcome key water-related research and development challenges. It is particularly relevant as food manufacturers turn to high-tech solutions to increase profitability in the face of supply chain issues and consumer concern over safety and sustainability. Like most manufacturers, food producers are increasingly impacted by supply chain shortages. The pandemic has exacerbated existing ingredient sourcing problems caused by climate change. With the Moisture Analysis Toolkit, manufacturers can use high-resolution moisture data to predict the effect of new ingredient candidates on moisture in the final product. “In a new supplier situation, our clients rely on the toolkit to make faster decisions and react quickly to new ingredient sourcing,” says METER Executive Vice President Takuya Ohki. “That’s what the toolkit is all about—faster, data-driven decisions that allow our clients to stay competitive in a fast-changing marketplace.” Ohki says that data-driven decision making is at the heart of the MAT, which includes tools for selecting the correct packaging and determining shelf life. “Historically, companies have tended to over-package and set a conservative best-by date. Now consumers are pushing companies to address issues of 30-40 percent waste in the food supply—while still demanding a mold-free product. Tackling safety and sustainability in tandem requires our best use of science. Too much of this research is still not implemented in industry. The Moisture Analysis Toolkit is something designed to make this science immediately accessible, to allow food manufacturers to solve these problems today.” The MAT takes advantage of a unique moisture map created by METER Group’s AQUALAB VSA. The VSA generates a high-resolution isotherm called a Dynamic Dewpoint Isotherm (DDI) curve. DDI curves can save companies months spent identifying a critical water activity in low and intermediate moisture food and pharmaceutical products, because they clearly illustrate the change in sorption properties. While competitor instruments use just the DVS method, METER Group’s MAT not only delivers DVS isotherms, but it also provides truly dynamic high-resolution DDI isotherm curves, uncovering granular details which have never been seen before. Unlocking access to these critical insights allows for more precise formulation, more accurate predictions, and more complete product knowledge. The business benefits and value are significant. For example, a dry ingredients company struggling with excessive labor, time, and space spent on shelf-life studies reduced the amount of physical shelf-life tests by 75 percent, cutting expenditures on testing from $300,000 to less than $50,000 per year. METER’s Moisture Analysis Toolkit also lets manufacturers work backward, picking a final water activity that maximizes shelf life and then getting guidance on specific formulation decisions around ingredient selection. This not only makes the formulation process more precise, but also speeds it up. A cold press bar company used the MAT with VSA-generated DDI isotherms to assess moisture migration during the R&D process, allowing them to release new products 5x faster and bring new flavors to market before competitors. “We see our clients succeeding from a profitability standpoint, but to me, that’s only part of the equation,” says Ohki. “The Moisture Analysis Toolkit empowers food and pharma companies to eliminate waste and inefficiencies across their respective supply chains on an unprecedented scale. That’s about more than profitability—it’s about putting existing science to work on the big problems we have to tackle as a society.” About METER Group METER Group, a Decagon and UMS combined company, delivers real-time, high-resolution data that fuels production and processes for the food quality, environmental research, urban and agriculture sectors. Through the power of its employees, METER combines science, engineering, and design expertise to turn physical measurements into useful information. Learn more at www.metergroup.com. Contact Details JMRConnect Mostafa Razzak +1 202-904-2048 m.razzak@jmrconnect.net

December 16, 2021 08:30 AM Eastern Standard Time

Lind to Provide $5M to Boost Prizma Sales to the Growth in Demand for Covid-19 Testing Across California

G Medical Innovations Holdings

TEL AVIV and NEW YORK, Dec. [16], 2021 G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the "Company") today announced the pricing of a private placement in the form of a convertible note in the principal amount of $5,000,000 that has a two-year maturity and a fixed conversion price. Proceeds to be used to launch 25 Covid-19 testing centers in California in Q1, 2022. The first six locations are currently in operation as of Wednesday, December 15, 2021. G Medical Innovations Holdings Ltd., a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, Known for its groundbreaking technology, remote patient monitoring devices and services utilized by hospitals and cardiologists across the country, GMedical’s innovative Prizma monitoring device will be offered direct-to consumer for the first time at these testing locations, as part of an aggressive company direct-to-consumer strategy. Prizma is a user-friendly cell phone-sized device that can help monitor user’s vital signs, providing to-the-minute readings for ECG, temperature, oxygen saturation, heart rate, stress levels and blood pressure, help track body weight and glucose levels. Data is presented directly to the user and the designated care provider. Prizma can also be prescribed by physicians to patients with cardiac or respiratory disease, diabetes and other health issues. With the explosive growth in demand for Covid testing across the country, G Medical expects its new California locations to boost Prizma sales. “By offering Prizma at our Covid19 testing sites we are empowering consumers to measure and monitor their vital signs post testing, in the comfort of their own home,” said G Medical CEO Dr. Yacov Geva. “This unique opportunity to introduce our Prizma device to customers face-to-face at the point of sale is an important step forward in our company’s direct-to-consumer initiative EF Hutton, division of Benchmark Investments, LLC, acted as exclusive placement agent for the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Forward-looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. For example, G Medical is using forward-looking statements when it discusses the use of proceeds from the private placement, plans to open as many as 25 Covid-19 testing centers in California in Q1, 2022, its direct-to-consumer strategy and the benefits and advantages of its Prizma medical device. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, G Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical is not responsible for the contents of third-party websites. Contact: G Medical Service +972 8-958-4777 service@gmedinnovations.com Contact Details G-Medical Innovations Holdings Ltd, Oren Cohen +972 8-958-4786 orenc@gmedinnovations.com Company Website https://gmedinnovations.com/

December 16, 2021 07:00 AM Eastern Standard Time

Variational AI Partners with the University of British Columbia and adMare BioInnovations to Develop COVID-19 Therapeutic

Variational AI

Variational AI, developer of state-of-the-art generative AI technology to redefine the economics of drug development by accelerating the discovery of novel and optimized small molecule therapeutics, today announced the company has generated and ordered compounds for validation in partnership with the University of British Columbia (UBC) and adMare BioInnovations to develop a novel SARS-CoV-2 Main Protease (3CLpro) inhibitor. The therapeutic is intended to be efficacious against the wild type and current variants of concern, including Delta and potentially Omicron, in the form of an antiviral pill. The COVID-19 drug discovery program is funded by Canada’s Digital Technology Supercluster, which is supported by the Canadian Ministry of Innovation, Science and Industry. “The Variational AI team is honored to partner with the University of British Columbia and adMare BioInnovations to work to address this most urgent medical need,” said Handol Kim, co-founder and CEO, Variational AI. “As society continues to grapple with COVID-19 variants, it is more important than ever to leverage the power of machine learning to accelerate our drug discovery efforts.” Variational AI has trained its generative AI algorithm on a large amount of COVID-19 data to generate new molecules and has ordered a number of compounds to be synthesized that are predicted to be potent and safe with fewer side effects. Variational AI uses a generative model known as Variational Autoencoder (VAE), which is able to optimize molecular properties more quickly and uses data far more efficiently. The company intends to license the antiviral compound to a partner to accelerate progress and get the therapeutics into clinics sooner. “We are proud to support Variational AI’s innovative approach to discovering an effective therapeutic for COVID-19,” said Sue Paish, CEO of the Digital Technology Supercluster. “While vaccines offer the first and best line of defense against COVID-19, the global community needs as many therapeutic options as possible to prevent fatalities and improve patient outcomes.” Generally, pills can be manufactured, distributed and stored more easily and cost-effectively than vaccines and are particularly well-suited to treat people in developing countries. In addition to COVID-19 and its variants, the resulting therapeutic may also be efficacious against other coronaviruses. “Our lab is committed to remaining at the forefront of applying computational methods to discover COVID-19 therapeutics, and our collaboration with Variational AI to leverage the company’s powerful AI adds a promising pipeline of novel and potent SARS-CoV-2 Main Protease inhibitors to the arsenal of antiviral options,” said Artem Cherkasov, Ph.D., professor of medicine, University of British Columbia. About Variational AI Variational AI uses state-of-the-art machine learning in a data-efficient method to rapidly generate novel and diverse compounds that are optimized for multiple properties to avoid the most common causes of drug attrition and increase clinical probability of success. Variational AI works with leading biopharmaceutical partners and is developing its own internal pipeline. To learn more, visit https://variational.ai. Contact Details Sage Morander +1 401-490-9700 variationalai@svmpr.com Company Website https://variational.ai/

December 15, 2021 10:00 AM Eastern Standard Time

Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022

Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical Officer and Board Director, Dr. Anthony Maida, will present at the upcoming 2 nd Annual TGF-β for Immuno-Oncology Drug Development Summit ( tgf-beta-summit.com ), which will take place virtually from January 25, 2022 to January 27, 2022. “There is significant worldwide interest in the clinical application of anti-TGF-β inhibitors, in combination with checkpoint inhibitors, as well as other immuno-oncology and chemotherapeutic options. We look forward to sharing the clinical promise of OT-101 in this setting.” noted Dr. Anthony Maida, Chief Clinical Office – Translational Medicine. TGF-β has been recognized by drug developers, for many years, as holding vast therapeutic potential due to its vital role in cell functioning and signaling. But its complex nature and its ability to be both tumor promoting and tumor suppressing has presented many obstacles for the industry. However, the field appears to be at a tipping point at present, with more candidates moving through clinical evaluation, pointing to an explosion of new data on the way. “I am excited that we have the opportunity to join other professionals in the field in January to explore novel insights into targeting TGF-β from discovery through clinical testing, and to learn from fellow colleagues such as Genentech, AbbVie, Takeda, and Mestag Therapeutics.” noted Dr. Vuong Trieu, CEO and Chairman of Oncotelic. OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients. Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β through therapeutic use of OT-101 carries significant potential to help both cancer and COVID patients in the future. Recent analyst report for Oncotelic can be accessed here: http://www.hillsresearch.com/wp-content/uploads/2021/12/OTLC-3Q21.pdf Recent Dr. Anthony Maida interview on our clinical program can be accessed here: https://www.asbestos.com/news/2021/12/07/mesothelioma-trial-covid-19-drug/ About Oncotelic Therapeutics Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) ("Oncotelic"), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. ("PointR") in November 2019. For more information, please visit www.oncotelic.com Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-beta therapeutics for oncology and virology This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate", "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company's product candidates and the potential use of the company's product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's annual report on Form 10-K filed with the SEC on April 15, 2021 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise. Contact Details Amit Shah ashah@oncotelic.com Company Website https://www.oncotelic.com

December 14, 2021 09:01 AM Eastern Standard Time

1 ... 163 164 165 166 167 ... 211

Back